相关实验视频
Updated: Jan 8, 2026

08:02
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
5.8K
免疫调节蛋白混合细胞外囊通过自负载的脊柱循环,用于口服炎性肠病治疗
Yeonju Lee1, Chaerim Yoo2, Kyung-Min Kim1
1Department of Life Science, Hanyang University, Seoul, 04763, Republic of Korea.
Bioactive materials
|December 24, 2025
概括
这项研究引入了一种用于炎症性肠病 (IBD) 的新型口服疗法,使用装载有功能性蛋白质的工程化细胞外囊泡 (EVs). 这种蛋白质-EV混合平台显示了增强IBD治疗的承诺,改善了治疗和疗效.
科学领域:
- 生物技术是生物技术.
- 药物运输 药物运输 药物运输
- 免疫学 免疫学 免疫学
背景情况:
- 细胞外囊泡 (EVs) 和治疗性蛋白质显示出口服输送的前景,但面临着整合的挑战.
- 协同治疗结果受到EV和蛋白质的精确功能整合的限制.
- 炎症性肠病 (IBD) 需要创新的治疗策略来有效地进行口服.
研究的目的:
- 为IBD治疗开发一种蛋白质混合,口服输送的EV策略.
- 创建可自负载,脊柱循环免疫调节蛋白质,以增强功能.
- 在临床前IBD模型中研究该平台的有效性.
主要方法:
- 计算指导设计和分割互联介导的骨干循环利用生成功能性蛋白质变体.
- 对T细胞蛋白氨酸酸酶 (ppTCPTP) 的酸酶域进行了循环处理,以获得更好的特性.
- 本地电动汽车装载了工程ppTCPTP,创造了抗酸性条件的蛋白质混合电动汽车,用于口服输送.
主要成果:
- ppTCPTP的骨干循环增强了它的膜透性,热稳定性和抗炎活性.
- 实现了对ppTCPTP的高效,高容量加载到原生电动汽车中.
- 蛋白质混合电动车在体外和体内表现出耐酸性,协同抗氧化和抗炎作用,减少了肠道炎症,并在结肠炎模型中恢复了上皮屏障完整性.
结论:
- 开发的自负载蛋白-EV平台为IBD治疗提供了强效和安全的口服生物药物.
- 该策略克服了整合EV和蛋白质的挑战,以实现协同治疗结果.
- 这些发现突显了这种创新方法在治疗炎症性肠病方面的翻译潜力.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
439
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
439
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
454
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
454
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
437
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
437
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
405
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
405
Inflammatory Bowel Disease II: Crohn's Disease
912
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
912
Drugs for Treatment of Ulcerative Colitis in IBD
416
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
416

